Document is current
Any future updates will be listed below
-
Authors
Kiyosue, Arihiro https://orcid.org/0000-0003-3201-7846
Inoue, Mariko
Takita, Yasushi
Nasu, Risa
Watada, Hirotaka
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05362058 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and Safety of Insulin Efsitora Versus Degludec in Adults with Type 2 Diabetes Who Are Insulin-Naïve: Japan Subgroup Analysis of QWINT-2
https://doi.org/10.1007/s13300-026-01860-w
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 10 December 2025
Accepted: 4 March 2026
First Online: 24 May 2026
Declarations
:
: Mariko Inoue, Yasushi Takita, and Risa Nasu are full-time employees of Eli Lilly Japan K.K. and own stock in Eli Lilly and Company. Arihiro Kiyosue has received honoraria from AstraZeneca, Eli Lilly and Company, and Sumitomo Pharma. Hirotaka Watada has received research funding from Abbott, Boehringer Ingelheim, Kowa, Lifescan Japan, Sanwa Kagaku Kenkyusyo, SBI Pharma, Sumitomo Pharma, Taisho Pharmaceutical, Takeda, and Teijin and lecture fees from Abbott, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly and Company, Embecta, GlaxoSmithKline, Kowa, Kyowa Kirin, Mitsubishi Tanabe, MSD, Novo Nordisk, Roche, Sanofi, Sanwa Kagaku Kenkyusyo, Sumitomo Pharma, Taisho Pharmaceutical, and Teijin. Hirotaka Watada is also an Editorial Board member of Diabetes Therapy . Hirotaka Watada was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: The protocol was approved by the independent ethics committee or institutional review board of each participating center, and the trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. All participants provided written informed consent.
